Tectonic Therapeutic's lead drug candidate has yielded very encouraging results in early clinical studies. Find out why TECX ...

About TX45, a long-acting Fc-relaxin fusion proteinTX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein ...

Mizuho initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $51 price target The company’s lead asset, TX45, is a ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN ...

Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart ...

Volenrelaxin belongs to a drug class known as relaxin mimetics, which includes Tectonic's (NASDAQ:TECX) lead candidate, TX45. An early-stage trial testing TX45 in pulmonary hypertension in heart ...

The presentation will highlight Phase 1b data for TX45, Tectonic’s lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF.

The presentation will highlight Phase 1b data for TX45, Tectonic’s lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF. The ...

The presentation will highlight Phase 1b data for TX45, Tectonic’s lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF.